The Incidence of Prostate Cancer and Risk of Progression in Black Men

Now Viewing

EP: 1.The Incidence of Prostate Cancer and Risk of Progression in Black Men

EP: 2.Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men

EP: 3.Representation of Black men with mHSPC in clinical trials

EP: 4.The current treatment landscape of mHSPC

EP: 5.Efficacy outcomes in Black patients from the ARANOTE trial

EP: 6.Safety data on Black patients from ARANOTE

EP: 7.Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients

EP: 8.Outcomes in Black patients receiving darolutamide plus ADT for mHSPC

EP: 9.Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions

EP: 10.The importance of studying efficacy and safety of treatment in Black patients with mHSPC

EP: 11.Improving diversity in future clinical trials for mHSPC

EP: 12.Remaining unmet needs in diverse populations with mHSPC

Epidemiology of Prostate Cancer in Black Men

Key Themes:

• Black men experience a 67% higher incidence of prostate cancer compared with all races/ethnicities.
• There is a more than 2-fold higher risk of mortality for Black men with prostate cancer.
• Significant racial disparity exists in both disease occurrence and outcomes.

Key Points for Physicians:

• Consider heightened vigilance in screening and early detection for Black male patients.
• Recognize the substantially elevated mortality risk when discussing prognosis and treatment urgency.
• Implement proactive follow-up protocols given the higher risk profile.

Notable Insights: The magnitude of disparity (67% higher incidence, >2× mortality) highlights prostate cancer as a particularly significant health equity issue for Black men.

Clinical Significance: These substantial disparities in incidence and mortality necessitate targeted approaches to screening, treatment, and follow-up care for Black men with prostate cancer.